|
STXBP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.37500000274571E-09 |
| Normal-vs-Stage3 |
2.48689957516035E-14 |
| Normal-vs-Stage4 |
1.62547753035369E-12 |
| Stage1-vs-Stage2 |
9.187000E-01 |
| Stage1-vs-Stage3 |
1.540610E-01 |
| Stage1-vs-Stage4 |
7.482100E-03 |
| Stage2-vs-Stage3 |
4.173800E-01 |
| Stage2-vs-Stage4 |
4.488400E-02 |
| Stage3-vs-Stage4 |
1.529450E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.73970000000501E-06 |
| Normal-vs-Asian |
4.21950252516012E-11 |
| Caucasian-vs-AfricanAmerican |
2.912400E-01 |
| Caucasian-vs-Asian |
8.255000E-01 |
| AfricanAmerican-vs-Asian |
4.237800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
5.587600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64346314335262E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
3.620800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.780200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.651700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.857000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.835000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.361200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.594000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.893400E-01 |
| Classical-VS-Follicular |
3.528000E-01 |
| Classical-VS-Other |
8.752000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
1.598810E-01 |
| Tall-VS-Other |
4.779800E-01 |
| Tall-VS-Normal |
1.12999998247432E-09 |
| Follicular-VS-Other |
8.885000E-01 |
| Follicular-VS-Normal |
6.7073002707474E-10 |
| Other-VS-Normal |
3.235300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
4.05786515500495E-13 |
| N0-vs-N1 |
2.476600E-01 |
|
|
